ESTEBAN, YRA G.

BSN II BLK 5
MEFENAMIC ACID
Generic Name: Mefenamic Acid
Classifications:central nervous system agent; analgesic; nsaid; antipyretic
Pregnancy Category:C

DESCRIPTION

Mefenamic Acid Capsules are a member of the fenamate group of nonsteroidal

anti-inflammatory drugs (NSAIDs). Each blue-banded, ivory capsule contains 250 mg
of mefenamic acid for oral administration. Mefenamic acid is a white to greyish-white,
odorless, microcrystalline powder with a melting point of 230°-231°C and water
solubility of 0.004% at pH 7.1. The chemical name is N-2,3-xylylanthranilic acid. The
molecular weight is 241.29. Its molecular formula is C15H15N02 and the structural
formula of mefenamic acid is:

Each capsule also contains lactose, NF. The capsule shell and/or band contains
citric acid, USP; D&C yellow No. 10; FD&C blue No. 1; FD&C red No. 3; FD&C yellow
No. 6; gelatin, NF; glycerol monooleate; silicon dioxide, NF; sodium benzoate, NF;
sodium lauryl sulfate, NF; titanium dioxide, USP.

PHARMACODYNAMICS

Mefenamic acid has analgesic, anti-inflammatory, and antipyretic properties.

The mechanism of action of mefenamic acid, like that of other NSAIDs, is not
completely understood but involves inhibition
of cyclooxygenase (COX-1 and COX-2).

Mefenamic acid is a potent inhibitor of prostaglandin synthesis in vitro.

Mefenamic acid concentrations reached during therapy have produced in vivo effects.
Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in
inducing pain in animal models. Prostaglandins are mediators of inflammation.
Because mefenamic acid is an inhibitor of prostaglandin synthesis, its mode of action
may be due to a decrease of prostaglandins in peripheral tissues.

PHARMACOKINETICS

Absorption

Mefenamic acid is rapidly absorbed after oral administration. In two 500-mg

single oral dose studies, the mean extent of absorption was 30.5 mcg/hr/mL (17%CV).
ESTEBAN, YRA G.
BSN II BLK 5
The bioavailability of the capsule relative to an IV dose or an oral solution has not
been studied.

Following a single 1-gram oral dose, mean peak plasma levels ranging from
10-20 mcg/mL have been reported. Peak plasma levels are attained in 2 to 4 hours
and the elimination half-life approximates 2 hours. Following multiple doses, plasma
levels are proportional to dose with no evidence of drug accumulation. In a multiple
dose trial of normal adult subjects (n= 6) receiving 1-gram doses of mefenamic acid
four times daily, steady-state concentrations of 20 mcg/mL were reached on the
second day of administration, consistent with the short half-life.

The effect of food on the rate and extent of absorption of mefenamic acid has not
been studied. Concomitant ingestion of antacids containing magnesium hydroxide
has been shown to significantly increase the rate and extent of mefenamic acid
absorption (see PRECAUTIONS: DRUG INTERACTIONS).

Distribution

Mefenamic acid has been reported as being greater than 90% bound to albumin.
The relationship of unbound fraction to drug concentration has not been studied. The
apparent volume of distribution (Vzss/F) estimated following a 500-mg oral dose of
mefenamic acid was 1.06 L/kg.

Based on its physical and chemical properties, mefenamic acid is expected to be

excreted in human breast milk (see PRECAUTIONS; Nursing Mothers).

Elimination

Metabolism

Mefenamic acid is metabolized by cytochrome P450 enzyme CYP2C9 to

3-hydroxymethyl mefenamic acid (Metabolite I). Further oxidation to a
3-carboxymefenamic acid (Metabolite II) may occur. The activity of these metabolites
has not been studied. The metabolites may undergo glucuronidation and mefenamic
acid is also glucuronidated directly. A peak plasma level approximating 20 mcg/mL
was observed at 3 hours for the hydroxy metabolite and its glucuronide (n= 6) after a
single 1-gram dose. Similarly, a peak plasma level of 8 mcg/mL was observed at 6-8
hours for the carboxy metabolite and its glucuronide.

Excretion

Approximately fifty-two percent of a mefenamic acid dose is excreted into the

urine primarily as glucuronides of mefenamic acid (6%), 3-hydroxymefenamic acid
(25%) and 3carboxymefenamic acid (21%). The fecal route of elimination accounts for
up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.

The elimination half-life of mefenamic acid is approximately two hours. Half-lives

of metabolites I and II have not been precisely reported, but appear to be longer than
the parent compound. The metabolites may accumulate in patients with renal or
hepatic failure. The mefenamic acid glucuronide may bind irreversibly to plasma
ESTEBAN, YRA G.
BSN II BLK 5
proteins. Because both renal and hepatic excretions are significant pathways of
elimination, dosage adjustments in patients with renal or hepatic dysfunction may be
necessary. Mefenamic acid should not be administered to patients with pre-existing
renal disease or in patients with significantly impaired renal function
(see WARNINGS; Renal Toxicity and Hyperkalemia).

SIDE EFFECTS

CNS:Drowsiness, insomnia, dizziness, nervousness, confusion, headache.

GI:Severe diarrhea, ulceration, and bleeding; nausea, vomiting, abdominal cramps,
flatus, constipation, hepatic toxicity.
Hematologic:Prolonged prothrombin time, severe autoimmune hemolytic anemia
(long-term use), leukopenia, eosinophilia, agranulocytosis, thrombocytopenic purpura,
megaloblastic anemia, pancytopenia, bone marrow hypoplasia.
Urogenital:Nephrotoxicity, dysuria, albuminuria, hematuria, elevation of BUN.
Skin:Urticaria, rash, facial edema.
SpecSenses:Eye irritation, loss of color vision (reversible), blurred vision, ear pain.
BodyWhole:Perspiration.
CV:Palpitation.
Respiratory:Dyspnea; acute exacerbation of asthma; bronchoconstriction (in patients
sensitive to aspirin).

NURSING IMPLICATIONS
Assessment & Drug Effects

 Assess patients who develop severe diarrhea and vomiting for

dehydration and electrolyte imbalance.
 Lab tests: With long-term therapy (not recommended) obtain
periodic complete blood counts, Hct and Hgb, and kidney function tests.
Patient & Family Education

 Discontinue drug promptly if diarrhea, dark stools, hematemesis,

ecchymoses, epistaxis, or rash occur and do not use again. Contact
physician.
 Notify physician if persistent GI discomfort, sore throat, fever, or
malaise occur.
 Do not drive or engage in potentially hazardous activities until
response to drug is known. It may cause dizziness and drowsiness.
 Monitor blood glucose for loss of glycemic control if diabetic.
 Do not breast feed while taking this drug without consulting
physician.
ESTEBAN, YRA G.
BSN II BLK 5

PARACETAMOL

Generic Name: Paracetamol, Acetaminophen

Brand Name: Biogesic, Panadol, Tylenol
Classification: Non-narcotic analgesic, Antipyretic
Uses:
1. Control of pain due to headache, earache, dysmenorrhea, arthralgia, myalgia,
musculoskeletal pain, arthritis, immunizations, teething, tonsillectomy
2. Reduce fever in viral and bacterial infections
3. As a substitute for aspirin in upper GI disease, bleeding disorders clients in
anticoagulant therapy and gouty arthritis

PHARMACOKINETICS
Paracetamol is readily absorbed from the gastrointestinal tract with peak plasma
concentrations occurring about 10 to 60 minutes after oral administration.
Paracetamol is distributed into most body tissues. Plasma protein binding is negligible
at usual therapeutic doses but increases with increasing doses. The elimination
half-life varies from about 1 to 3 hours.

Paracetamol is metabolised extensively in the liver and excreted in the urine

mainly as inactive glucuronide and sulfate conjugates. Less than 5% is excreted
unchanged. The metabolites of paracetamol include a minor hydroxylated
intermediate which has hepatotoxic activity. This intermediate metabolite is detoxified
by conjugation with glutathione, however, it can accumulate following paracetamol
overdosage (more than 150mg/kg or 10g total paracetamol ingested) and if left
untreated can cause irreversible liver damage.

Paracetamol is metabolised differently by premature infants, newborns, infants

and young children compared to adults, the sulfate conjugate being predominant.
ESTEBAN, YRA G.
BSN II BLK 5
PHARMACODYNAMICS/MECHANISM OF ACTION:
Paracetamol is a p-aminophenol derivative that exhibits analgesic and antipyretic
activity. It does not possess anti-inflammatory activity. Paracetamol is thought to
produce analgesia through a central inhibition of prostaglandin synthesis.

Possible Adverse Reactions (seen with prolonged use, high dose)

1. Hepatic toxicity - toxicity even seen in low doses in preterm infants and those
receiving prolonged parenteral nutrition.
2. Thrombocytopenia and neutropenia.
3. Allergic skin pruritic rash.
4. Vomiting and abdominal pain usually occur within 2 - 3 hr after administration
of toxic doses.
5. Severe poisoning - CNS stimulation followed by CNS depression, hypothermia;
low BP; and circulatory failure.
6. Side-Effects:
7. Minimal GI upset.
8. Methemoglobinemia
9. Hemolytic Anemia
10. Pancytopenia
11. Leukopenia
12. Urticaria
13. CNS stimulation
14. Hypoglycemic coma
15. Jaundice
16. Glissitis
17. Drowsiness

NURSING IMPLICATIONS
1. Acetaminophen is intended for temporary use only - should not be given for
more than 4 - 5 days without physician reassessment.
2. Severe hepatic damage is sometimes not apparent until several days after
overdosage.
3. . Give oral dose with the nearest feed to reduce GI upset or as needed.
4. Do not exceed 4gm/24hr. in adults and 75mg/kg/day in children.
ESTEBAN, YRA G.
BSN II BLK 5
5. Do not take for >5days for pain in children, 10 days for pain in adults, or more
than 3 days for fever in adults.
6. Extended-Release tablets are not to be chewed.
7. Monitor CBC, liver and renal functions.
8. Assess for fecal occult blood and nephritis.
9. Avoid using OTC drugs with Acetaminophen.
10. Take with food or milk to minimize GI upset.
11. Report N&V. cyanosis, shortness of breath and abdominal pain as these are
signs of toxicity.
12. Report paleness, weakness and heart beat skips
13. Report abdominal pain, jaundice, dark urine, itchiness or clay-colored stools.
14. Phenmacetin may cause urine to become dark brown or wine-colored.
15. Report pain that persists for more than 3-5 days
16. Avoid alcohol.
17. This drug is not for regular use with any form of liver disease.